|
16 Companies |
|
11 Products |
|
11 Products |
|
14 Mechanisms of Action |
|
0 Trials |
|
39 News |
|
- ||||| azathioprine / Generic mfg.
Trial termination: Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (clinicaltrials.gov) - Dec 13, 2018
P4, N=131, Terminated, Sponsor: University Medical Center Groningen
Active, not recruiting --> Terminated
- | Rituxan (rituximab) / Roche
Trial completion: MAINRITSAN 2: Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (clinicaltrials.gov) - Mar 2, 2018
P3, N=166, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: RAVELOS: Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=67, Terminated, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed N=180 --> 67
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Trial primary completion date: An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=100, Completed, Sponsor: Genentech, Inc.
N=180 --> 67 Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jul 2015
- ||||||| Benlysta (belimumab) / GSK
Trial completion, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Feb 11, 2017
P3, N=116, Completed, Sponsor: Human Genome Sciences Inc., a GSK Company
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jul 2015 Active, not recruiting --> Completed
- ||||||| Nucala (mepolizumab) / GSK
Trial completion: A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (clinicaltrials.gov) - Nov 9, 2016
P3, N=136, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial primary completion date: MAINRITSAN 2: Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (clinicaltrials.gov) - Sep 15, 2016
P3, N=166, Active, not recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Trial primary completion date: Aug 2016 --> Apr 2016
- ||||| Benlysta (belimumab) / GSK
Enrollment change, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Jan 20, 2016
P3, N=100, Active, not recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
Trial primary completion date: Aug 2016 --> Apr 2016 N=400 --> 100
- ||||| Nucala (mepolizumab) / GSK
Enrollment closed: A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (clinicaltrials.gov) - Oct 13, 2015
P3, N=130, Active, not recruiting, Sponsor: GlaxoSmithKline
N=400 --> 100 Recruiting --> Active, not recruiting
- ||||| Benlysta (belimumab) / GSK
Enrollment closed, Trial primary completion date, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Sep 24, 2015
P3, N=400, Active, not recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2017
- blisibimod (A-623) / Anthera Pharma
Enrollment change, Trial withdrawal: BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (clinicaltrials.gov) - Aug 12, 2015
P2, N=0, Withdrawn, Sponsor: Anthera Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2017 N=100 --> 0 | Not yet recruiting --> Withdrawn
- Orencia (abatacept) / BMS
Trial primary completion date: ABAVAS: Abatacept in ANCA Associated Vasculitis (clinicaltrials.gov) - Jun 11, 2015
P2, N=7, Terminated, Sponsor: Imperial College London
N=100 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2010 --> Nov 2008
- Rituxan (rituximab) / Roche
Trial primary completion date: MAINRITSAN 2: Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (clinicaltrials.gov) - Apr 30, 2015
P3, N=166, Active, not recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Dec 2010 --> Nov 2008 Trial primary completion date: Aug 2017 --> Aug 2016
- Trial completion: DAP12WEGENER: Study of One Protein Implicated in Wegener Disease (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=138, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Aug 2017 --> Aug 2016 Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: SPARROW: Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (clinicaltrials.gov) - Jan 22, 2015
P3, N=4, Terminated, Sponsor: Nordic Pharma SAS
Active, not recruiting --> Completed N=216 --> 4 | Suspended --> Terminated | Trial primary completion date: Apr 2014 --> Nov 2012; Change of design consideration
- ||| azathioprine / Generic mfg.
Enrollment closed, Trial primary completion date: Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (clinicaltrials.gov) - Jan 2, 2015
P4, N=180, Active, not recruiting, Sponsor: University Medical Centre Groningen
N=216 --> 4 | Suspended --> Terminated | Trial primary completion date: Apr 2014 --> Nov 2012; Change of design consideration Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Jun 2014
- Clinical: Educational Needs of Patients With Systemic Vasculitis (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=386, Completed, Sponsor: University of South Florida
- Clinical: Reproductive Health in Men and Women With Vasculitis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=467, Completed, Sponsor: University of South Florida
- || Trial suspension: SPARROW: Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (clinicaltrials.gov) - Mar 13, 2014
P3, N=216, Suspended, Sponsor: Nordic Pharma SAS
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Jun 2014 Recruiting --> Suspended
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies (clinicaltrials.gov) - Feb 22, 2014
P1, N=10, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Suspended No longer recruiting --> Completed
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion: WGET: Etanercept for Wegener's Granulomatosis (clinicaltrials.gov) - Feb 19, 2014
P2/3, N=181, Completed, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
No longer recruiting --> Completed No longer recruiting --> Completed
- |||||| Nucala (mepolizumab) / GSK
Enrollment open: A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (clinicaltrials.gov) - Feb 12, 2014
P3, N=130, Recruiting, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- ||| blisibimod (A-623) / Anthera Pharma
Trial initiation date: BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (clinicaltrials.gov) - Jan 30, 2014
P2, N=100, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Dec 2013 --> Dec 2014
- Enrollment closed: DAP12WEGENER: Study of One Protein Implicated in Wegener Disease (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Initiation date: Dec 2013 --> Dec 2014 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche
Enrollment closed: MAINRITSAN 2: Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (clinicaltrials.gov) - Jan 1, 2014
P3, N=166, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Nucala (mepolizumab) / GSK
New P3 trial: A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (clinicaltrials.gov) - Dec 23, 2013
P3, N=130, Recruiting, Sponsor: GlaxoSmithKline
- |||||| Benlysta (belimumab) / GSK
Enrollment open, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Aug 21, 2013
P3, N=400, Recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche
Trial completion: MAINRITSAN: Efficacy Study of Two Treatments in the Remission of Vasculitis (clinicaltrials.gov) - Aug 1, 2013
P3, N=117, Completed, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed: An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=100, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Benlysta (belimumab) / GSK
Enrollment change, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Dec 5, 2012
P3, N=400, Recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
Recruiting --> Active, not recruiting N=300 --> 400
- || Rituxan (rituximab) / Roche
New P3 trial: MAINRITSAN 2: Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (clinicaltrials.gov) - Nov 20, 2012
P3, N=166, Active, not recruiting, Sponsor: Assistance Publique - H
- Orencia (abatacept) / BMS
Trial completion: Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis (clinicaltrials.gov) - Oct 22, 2012
P1/2, N=20, Completed, Sponsor: University of Pennsylvania
N=300 --> 400 Active, not recruiting --> Completed
- |||||||||| Benlysta (belimumab) / GSK
New P3 trial, Combination therapy: BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) - Aug 9, 2012
P3, N=400, Recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
- ||||| blisibimod (A-623) / Anthera Pharma
New P2 trial: BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (clinicaltrials.gov) - May 13, 2012
P2, N=100, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
- ||| New P3 trial: SPARROW: Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (clinicaltrials.gov) - Oct 3, 2011
P3, N=216, Suspended, Sponsor: Nordic Pharma SAS
- prednisone / Generic mfg.
Clinical: CORTAGE: Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years (clinicaltrials.gov) - Aug 28, 2011
P4, N=108, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: RAVE: Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis (clinicaltrials.gov) - Aug 23, 2011
P2/3, N=197, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed